Get an overview of the status and development of HAEMATO AG. Here you will find information on the group and its developments in recent years.

Interim Report 2022

HAEMATO AG was able to continue its profitable growth course in the „Specialty Pharma“ and „Lifestyle & Aesthetics“ segments in the first half of 2022. This was achieved despite the fact that the special effects from the COVID-19 Diagnostics business unit, which made an extraordinarily positive contribution to earnings in the previous year, have largely disappeared.


Get an overview of published interim and annual reports of HAEMATO AG.

Annual Report 2021

Interim Report 2021

Annual Report 2020

Interim Report 2020

Annual Report 2019

Interim Report 2019

Annual Report 2018

Interim Report 2018

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us